Clinical TrialMay 30, 2026, 08:02 AM
Replimune RP1+nivolumab shows 3-year OS of 47.8% in melanoma
AI Summary
Replimune Group, Inc. presented positive 3-year overall survival data from its IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma patients. The study showed a median overall survival of 32.9 months, with nearly half of all treated patients alive at three years. Responders demonstrated even greater durability, with 83.5% alive at three years, highlighting a significant and durable benefit in a difficult-to-treat population. The combination also maintained a favorable safety profile.
Key Highlights
- RP1 plus nivolumab achieved a median overall survival (mOS) of 32.9 months.
- 47.8% of all treated patients remained alive at 3 years.
- 83.5% of responders to RP1 plus nivolumab were alive at 3 years.
- The objective response rate (ORR) was 33.6%.
- The median duration of response (DOR) was 24.8 months.
- 44.8% of responders maintained their response at 3 years.
- The combination demonstrated a favorable and manageable safety profile.
Price Impact
More from REPL